Volume : 7, Issue : 6, June - 2018

TO STUDY THE ADVERSE DRUG REACTIONS (ADR) & TO FIND OUT THE EFFECT OF ADR IN TB PATIENTS REGISTERED UNDER RNTCP IN KARAD TU.

Vandana Bhoi, Anil Bhoi

Abstract :

<p>&nbsp;BACKGROUND: Anti tubercular treatment (ATT) exhibit greater level of a efficacy with a satisfactory degree of</p> <div>toxicity, however combination treatment may produce severe adverse drug reaction (ADR). ADR leads to decrease</div> <div>in patient compliance &amp; adherence .So close monitoring of ADR &amp; it‘s effective management needed.</div> <div>Objective- To study of adverse drug reactions (ADR) in tuberculosis (TB) patients registered under RNTCP and the effect of adverse drug</div> <div>reaction.</div> <div>Material &amp; Methods- This is longitudinal (Prospective) study done during January2008 to June2009 Total 806 patients who registered in 9</div> <div>PHCs, Sub District Hospital, Krishna Hospital &amp; 6DMCs with 3 ICTCs under Karad TU as study subjects.</div> <div>Result &amp; Observations - It was 513 (63.6%) patients had adverse reactions while 293 (36.35%) had no adverse reactions. Out of 513</div> <div>patients 486 (60.30%)had gastritis, 33 (4.09%) had gastritis and joint pain, 49 (6.09%) had gastritis and skin rash, 62 (7.69% ) had</div> <div>itching, 43 (5.33%) had joint pain. Thus gastritis was being the most common adverse Conclusion- There was no any signi􀃶cantly</div> <div>association seen between ADR and gender in this study. It was observed that 147(21.4%) patients continued DOTS treatment after giving</div> <div>treatment for ADR, 240(34.9%) continued DOTS treatment even if they were not treated for their ADR, 301(43.8%) continued DOTS</div> <div>treatment after given reassurance foe ADR.</div> <div>Conclusion- Gastritis 480 (60.30%) was the most commonest adverse reaction seen as well as most of the adverse reactions was</div> <div>seen in intensive phase i.e. in 􀃶rst 2 months. There was not association in ADR and gender. In this study, 147(21.4%) patients continued</div> <div>DOTS treatment after giving treatment for ADR, 240(34.9%) continued DOTS treatment even if they were not treated for their ADR,</div> <div>301(43.8%) continued DOTS treatment after given reassurance for ADR. Most of the adverse reactions were in intensive phase of treatment</div> <div>i.e. that in 􀃶rst 2 months. Gastritis was present in intensive phase as well as initial months of continuation phase treatment.</div>